Why does IHC remain so popular for CDx development?

The topic of IHC came up recently. Specifically, why is it used so frequently for companion diagnostic development.

Read More

New China operation

December 30th was an exciting day for NeoGenomics as we got the keys to our new facility in Suzhou, China.

Read More

CRO and Clinical Reference Laboratory Commercial Incentives

One of the challenges developing a companion diagnostic is creating a test that runs well in both clinical trials, and following regulatory approval, clinical testing laboratories Unfortunately, in

Read More

Oncology Clinical Trials During a Pandemic

2020 has really been a year that doesn’t quit, hasn’t it?

Read More
Written By:
Madhu Ghosh

It’s a Great Clinical Trial Assay

While there are many great tools and technologies available to support drug development, the number of platforms used for CDx development remains very limited.

Read More

Is It Validated?

NeoGenomics has a menu of >600 assays across many different technologies and approaches.

Read More

Liquid Biopsy Testing for PIK3CA Mutation

For years, researchers have looked into liquid biopsy as a potentially useful tool to help Health Care Providers assess a patient’s response to treatment, monitor cancer recurrence and even detect

Read More

A spotlight on CDx development

NeoGenomics will share several posts focusing on CDx development.

Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients